Total Payments
$20,985
2024 Payments
$158.67
Companies
9
Transactions
37
Medicare Patients
886
Medicare Billing
$209,424
Payment Breakdown by Category
Consulting$17,566 (83.7%)
Research$1,424 (6.8%)
Travel$1,070 (5.1%)
Food & Beverage$914.90 (4.4%)
Education$10.85 (0.1%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $17,566 | 8 | 83.7% |
| Unspecified | $1,424 | 8 | 6.8% |
| Travel and Lodging | $1,070 | 2 | 5.1% |
| Food and Beverage | $914.90 | 18 | 4.4% |
| Education | $10.85 | 1 | 0.1% |
Payments by Type
General
$19,562
29 transactions
Research
$1,424
8 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Kite Pharma, Inc. | $15,113 | 19 | $0 (2023) |
| MorphoSys AG | $4,326 | 3 | $0 (2023) |
| GlaxoSmithKline, LLC. | $1,156 | 6 | $0 (2019) |
| F. Hoffmann-La Roche AG | $158.67 | 1 | $0 (2024) |
| GENZYME CORPORATION | $86.48 | 1 | $0 (2018) |
| Astellas Pharma US Inc | $56.30 | 3 | $0 (2021) |
| OPKO Pharmaceuticals, LLC | $43.15 | 1 | $0 (2019) |
| Otsuka America Pharmaceutical, Inc. | $34.30 | 2 | $0 (2021) |
| Merck Sharp & Dohme LLC | $10.85 | 1 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $158.67 | 1 | F. Hoffmann-La Roche AG ($158.67) |
| 2023 | $7,325 | 7 | Kite Pharma, Inc. ($6,203) |
| 2022 | $4,783 | 3 | Kite Pharma, Inc. ($3,170) |
| 2021 | $1,654 | 4 | MorphoSys AG ($1,602) |
| 2020 | $5,207 | 5 | Kite Pharma, Inc. ($5,207) |
| 2019 | $1,502 | 13 | GlaxoSmithKline, LLC. ($1,156) |
| 2018 | $355.96 | 4 | Kite Pharma, Inc. ($269.48) |
All Payment Transactions
37 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/31/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $158.67 | Research |
| Study: LEO DLBCL R R | ||||||
| 05/15/2023 | Kite Pharma, Inc. | Tecartus (Drug) | Consulting Fee | Cash or cash equivalent | $5,020.00 | General |
| Category: CELLT | ||||||
| 04/28/2023 | Kite Pharma, Inc. | Tecartus (Drug) | Food and Beverage | In-kind items and services | $49.99 | General |
| Category: CELLT | ||||||
| 04/28/2023 | Kite Pharma, Inc. | Tecartus (Drug) | Food and Beverage | In-kind items and services | $49.99 | General |
| Category: CELLT | ||||||
| 04/28/2023 | Kite Pharma, Inc. | Tecartus (Drug) | Food and Beverage | In-kind items and services | $13.14 | General |
| Category: CELLT | ||||||
| 04/27/2023 | Kite Pharma, Inc. | Tecartus (Drug) | Travel and Lodging | In-kind items and services | $765.95 | General |
| Category: CELLT | ||||||
| 04/27/2023 | Kite Pharma, Inc. | Tecartus (Drug) | Travel and Lodging | In-kind items and services | $303.97 | General |
| Category: CELLT | ||||||
| 02/09/2023 | MorphoSys AG | MONJUVI (Drug) | Consulting Fee | Cash or cash equivalent | $1,122.00 | General |
| Category: Oncology | ||||||
| 06/08/2022 | Merck Sharp & Dohme LLC | PREVYMIS (Drug) | Education | In-kind items and services | $10.85 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 04/15/2022 | Kite Pharma, Inc. | Yescarta (Drug) | Consulting Fee | Cash or cash equivalent | $3,170.00 | General |
| Category: CELLT | ||||||
| 04/14/2022 | MorphoSys AG | MONJUVI (Drug) | Consulting Fee | Cash or cash equivalent | $1,602.00 | General |
| Category: Oncology | ||||||
| 12/17/2021 | MorphoSys AG | — | Consulting Fee | Cash or cash equivalent | $1,602.00 | General |
| 07/19/2021 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $14.74 | General |
| Category: PSYCHIATRY | ||||||
| 06/18/2021 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $19.56 | General |
| Category: PSYCHIATRY | ||||||
| 02/11/2021 | Astellas Pharma US Inc | MYRBETRIQ (Drug) | Food and Beverage | In-kind items and services | $17.61 | General |
| Category: UROLOGY | ||||||
| 11/16/2020 | Kite Pharma, Inc. | Tecartus (Drug) | Consulting Fee | Cash or cash equivalent | $1,700.00 | General |
| Category: CELLT | ||||||
| 05/15/2020 | Kite Pharma, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,340.00 | General |
| 03/19/2020 | Kite Pharma, Inc. | Yescarta (Drug) | Consulting Fee | Cash or cash equivalent | $2,010.00 | General |
| Category: CELLT | ||||||
| 02/20/2020 | Kite Pharma, Inc. | Yescarta (Drug) | Food and Beverage | In-kind items and services | $31.58 | General |
| Category: CELLT | ||||||
| 02/19/2020 | Kite Pharma, Inc. | Yescarta (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: CELLT | ||||||
| 12/08/2019 | Kite Pharma, Inc. | Yescarta (Drug) | Food and Beverage | In-kind items and services | $112.80 | General |
| Category: ONC | ||||||
| 12/06/2019 | Kite Pharma, Inc. | — | — | Cash or cash equivalent | $108.81 | Research |
| Study: A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-X19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (ZUMA 2) | ||||||
| 11/21/2019 | Astellas Pharma US Inc | MYRBETRIQ (Drug) | Food and Beverage | In-kind items and services | $15.81 | General |
| Category: UROLOGY | ||||||
| 11/07/2019 | OPKO Pharmaceuticals, LLC | Rayaldee (Drug) | Food and Beverage | In-kind items and services | $43.15 | General |
| Category: Hyperparathyroidism | ||||||
| 10/10/2019 | GlaxoSmithKline, LLC. | — | — | In-kind items and services | $768.68 | Research |
| Study: MASTER PROTOCOL TO ASSESS THE SAFETY AND ANTITUMOR ACTIVITY OF GENETIC | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| MASTER PROTOCOL TO ASSESS THE SAFETY AND ANTITUMOR ACTIVITY OF GENETIC | GlaxoSmithKline, LLC. | $1,156 | 6 |
| LEO DLBCL R R | F. Hoffmann-La Roche AG | $158.67 | 1 |
| A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-X19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (ZUMA 2) | Kite Pharma, Inc. | $108.81 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 270 | 695 | $298,012 | $55,089 |
| 2022 | 7 | 202 | 707 | $295,550 | $54,413 |
| 2021 | 7 | 215 | 715 | $294,210 | $55,862 |
| 2020 | 5 | 199 | 607 | $252,483 | $44,060 |
Total Patients
886
Total Services
2,724
Medicare Billing
$209,424
Procedure Codes
26
All Medicare Procedures & Services
26 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 121 | 409 | $156,651 | $28,098 | 17.9% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 31 | 139 | $59,876 | $12,303 | 20.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 51 | 51 | $37,626 | $6,559 | 17.4% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 18 | 43 | $12,897 | $2,532 | 19.6% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 15 | 16 | $13,464 | $2,066 | 15.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 16 | 18 | $9,162 | $1,916 | 20.9% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2023 | 18 | 19 | $8,336 | $1,615 | 19.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 92 | 420 | $158,428 | $29,850 | 18.8% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 29 | 198 | $84,150 | $15,092 | 17.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 30 | 30 | $21,832 | $3,842 | 17.6% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 13 | 17 | $14,161 | $2,519 | 17.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 12 | 13 | $6,561 | $1,421 | 21.7% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2022 | 14 | 17 | $7,378 | $1,335 | 18.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 12 | 12 | $3,040 | $352.78 | 11.6% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 79 | 329 | $122,297 | $23,252 | 19.0% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 31 | 246 | $103,638 | $19,015 | 18.3% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 26 | 51 | $25,407 | $5,636 | 22.2% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 23 | 23 | $16,512 | $3,088 | 18.7% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 31 | 40 | $10,085 | $2,005 | 19.9% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 13 | 13 | $10,701 | $1,821 | 17.0% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2021 | 12 | 13 | $5,570 | $1,045 | 18.8% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 36 | 250 | $102,530 | $19,829 | 19.3% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 87 | 213 | $77,691 | $11,703 | 15.1% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 45 | 108 | $53,186 | $8,931 | 16.8% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 14 | 14 | $9,870 | $1,804 | 18.3% |
About Dr. Umar Farooq, MD
Dr. Umar Farooq, MD is a Hematology & Oncology healthcare provider based in Iowa City, Iowa. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/29/2007. The National Provider Identifier (NPI) number assigned to this provider is 1336333673.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Umar Farooq, MD has received a total of $20,985 in payments from pharmaceutical and medical device companies, with $158.67 received in 2024. These payments were reported across 37 transactions from 9 companies. The most common payment nature is "Consulting Fee" ($17,566).
As a Medicare-enrolled provider, Farooq has provided services to 886 Medicare beneficiaries, totaling 2,724 services with total Medicare billing of $209,424. Data is available for 4 years (2020–2023), covering 26 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Iowa City, IA
- Active Since 08/29/2007
- Last Updated 12/11/2014
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1336333673
Products in Payments
- Tecartus (Drug) $7,903
- Yescarta (Drug) $5,648
- MONJUVI (Drug) $2,724
- MOZOBIL (Drug) $86.48
- MYRBETRIQ (Drug) $56.30
- Rayaldee (Drug) $43.15
- REXULTI (Drug) $34.30
- PREVYMIS (Drug) $10.85
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Iowa City
Brian Link, Md, MD
Hematology & Oncology — Payments: $52,865
Hematology & Oncology $52,865
George Weiner, Md, MD
Hematology & Oncology — Payments: $13,379
Hematology & Oncology $13,379
Usha Perepu, Mbbs, MBBS
Hematology & Oncology — Payments: $10,632
Hematology & Oncology $10,632
Dr. Laurel Lyckholm, M.d, M.D
Hematology & Oncology — Payments: $7,046
Hematology & Oncology $7,046
Guido Tricot, Md, MD
Hematology & Oncology — Payments: $5,537
Hematology & Oncology $5,537
Christopher Strouse, M.d, M.D
Hematology & Oncology — Payments: $4,364
Hematology & Oncology $4,364